Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…